Skip to main content

Table 3 Model fit statistics

From: Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis

Year

Fixed effects

Random effects

Reference case: RCTs with 100% HER2+ patients and HER2+ subgroups

2008

DIC = 1.69

TotResDev = 2.99 vs. 4

DIC = 3.19

TotResDev = 3.74 vs. 4

Heterogeneity SD (95% CI) = 0.68 (0.01 to 4.55)

2010

DIC = 17

TotResDev = 10.63 vs. 10

DIC = 17.96

TotResDev = 9.66 vs. 10

Heterogeneity SD (95% CI) = 0.37 (0.02 to 2.41)

2012

DIC = 28.67

TotResDev = 19.63 vs. 16

DIC = 26.29

TotResDev = 14.64 vs. 16

Heterogeneity SD (95% CI) = 0.31 (0.05 to 1.16)

2014

DIC = 25.24

TotResDev = 25.67 vs. 25

DIC = 25.76

TotResDev = 23.27 vs. 25

Heterogeneity SD (95% CI) = 0.12 (0.01 to 0.43)

2016

DIC = 28.17

TotResDev = 33.94 vs. 34

DIC = 28.17

TotResDev = 32.07 vs. 34

Heterogeneity SD (95% CI) = 0.08 (0.01 to 0.27)

  1. CI confidence interval, DIC deviance information criterion, HER2+ human epidermal growth factor receptor 2-positive, RCT randomized controlled trial, SD standard deviation, TotResDev total residual deviance